Background: Valganciclovir prophylaxis is reportedly associated with a low incidence of
ganciclovir‐resistant cytomegalovirus (CMV). We assessed the incidence, clinical features …

We investigated the emergence of cytomegalovirus (CMV) ganciclovir-resistance mutations
in 301 high-risk solid-organ transplant (SOT) recipients after oral prophylaxis, for 100 days …

Cytomegalovirus (CMV) infection is an important complication of solid-organ transplantation.
The availability of potent antiviral therapies has decreased the incidence of CMV disease …

Despite remarkable advances in the diagnostic and therapeutic modalities for its
management, cytomegalovirus (CMV) remains one of the most important pathogens …

Background Experience with high-dose ganciclovir for the management of resistant
cytomegalovirus (CMV) replication in transplant patients is limited despite its adoption as an …

Background The rate of cytomegalovirus (CMV) mutations conferring ganciclovir resistance
was assessed in a trial comparing intravenous ganciclovir and oral valganciclovir for …

We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in
preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant …

Background. Ganciclovir‐resistant (GCV‐R) cytomegalovirus (CMV) is now being reported
with increasing frequency in solid organ transplant recipients. Objective. To describe the …

Clinical consequences of ganciclovir resistant cytomegalovirus (CMV) infections were
studied during 2 large prophylactic trials consisting of 100 days of valganciclovir or …

Background Ganciclovir‐resistant cytomegalovirus (GCV‐R CMV) is an emerging challenge
among solid organ transplant (SOT) recipients. The literature suggests that about 1% of …